AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8295364 — intervention group
Group type: EXPERIMENTAL
Intervention: PhXA41
Number of subjects: 35
Study 3631982 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocolloid occlusive dressing (HCD)
Number of subjects: 26
Study 3631982 — intervention group
Group type: COMPARATOR
Intervention: Fluocinolone acetonide cream (twice-daily applications)
Number of subjects: 26
Study 3631982 — intervention group
Group type: COMPARATOR
Intervention: Erythemogenic ultraviolet B treatment
Number of subjects: 26
Study 31868907 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular panel-guided treatment for selected mutations
Number of subjects: 0
Study 31868907 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 28332914 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory (WM) training program
Number of subjects: 34
Study 28332914 — intervention group
Group type: COMPARATOR
Intervention: Normal class activities (Control)
Number of subjects: 34
Study 28125168 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg daily oral Prednisone for one month
Number of subjects: 90
Study 28125168 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg daily oral Prednisone for one month
Number of subjects: 90
Study 28125168 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg daily oral Prednisone for one month
Number of subjects: 90
Study 27275233 — intervention group
Group type: COMPARATOR
Intervention: ICS/LABA
Number of subjects: 56
Study 27275233 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS/LABA plus Montelukast
Number of subjects: 56
Study 23040588 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 to n-6 polyunsaturated fatty acids ratio
Number of subjects: 101
Study 21769136 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated care intervention (INT) with counseling and case management for up to 9 months
Number of subjects: 101
Study 21769136 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SC)
Number of subjects: 101
Study 19336639 — intervention group
Group type: EXPERIMENTAL
Intervention: Sliding‐scale regular insulin (SSRI) alone (n = 25)
Number of subjects: 50
Study 19336639 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (n = 25)
Number of subjects: 50
Study 19336639 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 16397283 — intervention group
Group type: EXPERIMENTAL
Intervention: Otamixaban
Number of subjects: 0
Study 15000515 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group treatment
Number of subjects: 128
Study 15000515 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactional group treatment
Number of subjects: 128
Study 15000515 — intervention group
Group type: COMPARATOR
Intervention: Psychosocial and biological indicators
Number of subjects: 128
Study 11080319 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicarious experience through peer support (experimental group)
Number of subjects: 56
Study 11080319 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 56
Study 8706452 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop control of airway occlusion pressure at 0.1 sec (P0.1)
Number of subjects: 8
Study 8706452 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-support ventilation adjustments
Number of subjects: 8
Study 1850686 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of [3H]noradrenaline
Number of subjects: 43
Study 1850686 — intervention group
Group type: COMPARATOR
Intervention: Neuronal uptake blockade with desipramine
Number of subjects: 43
Study 1850686 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental arithmetic and isometric handgrip exercise
Number of subjects: 43
Study 1850686 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest in supine position
Number of subjects: 43
Study 6645778 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric convulsive therapy (ECT)
Number of subjects: 9
Study 6645778 — intervention group
Group type: COMPARATOR
Intervention: Premedication only (Control)
Number of subjects: 9
Study 31396757 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking (for 30 min) immediately after the meal
Number of subjects: 48
Study 31396757 — intervention group
Group type: EXPERIMENTAL
Intervention: Bodyweight exercises (3 sets of 10 squats, 10 push-ups, 10 lunges, 10 sit-ups) immediately after the meal
Number of subjects: 48
Study 31396757 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing still (for 30 min) immediately after the meal
Number of subjects: 48
Study 31396757 — intervention group
Group type: COMPARATOR
Intervention: Standing, walking, or bodyweight exercise conducted immediately before the meal
Number of subjects: 48
Study 31396757 — intervention group
Group type: COMPARATOR
Intervention: Standing, walking, or bodyweight exercise conducted 30 min after the meal
Number of subjects: 48
Study 31525122 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic information about nicotine addiction and lung cancer (n = 314)
Number of subjects: 392
Study 31525122 — intervention group
Group type: COMPARATOR
Intervention: News article about pharmacy's decision to stop selling tobacco (n = 78)
Number of subjects: 392
Study 27378477 — intervention group
Group type: EXPERIMENTAL
Intervention: Small access window (6×6 mm) + bone filling using a special device
Number of subjects: 16
Study 27378477 — intervention group
Group type: COMPARATOR
Intervention: Large access window (10×8 mm) + manual bone filling
Number of subjects: 16
Study 25828280 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone 0.1 mg/kg
Number of subjects: 60
Study 25828280 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 0.1 ml/kg (Control)
Number of subjects: 60
Study 23312881 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept 4 mg/kg with irinotecan-LV5FU2 every 2 weeks
Number of subjects: 27
Study 23312881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 21166834 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurochemical intervention involving L-theanine and 5-hydroxytryptophan
Number of subjects: 0
Study 19692885 — intervention group
Group type: EXPERIMENTAL
Intervention: LigaSure (5 to 10 mm)
Number of subjects: 32
Study 19692885 — intervention group
Group type: COMPARATOR
Intervention: Endodissector and endoclip
Number of subjects: 32
Study 17329041 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent condom use with exclusive main partner
Number of subjects: 1770
Study 17329041 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent condom use with multiple partners
Number of subjects: 1770
Study 17329041 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipating a positive response to requests for condom use
Number of subjects: 1770
Study 17329041 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner support of condom use
Number of subjects: 1770
Study 17329041 — intervention group
Group type: EXPERIMENTAL
Intervention: Main partner's pregnancy desires
Number of subjects: 1770
Study 17329041 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle sharing with a main partner
Number of subjects: 1770
Study 17329041 — intervention group
Group type: EXPERIMENTAL
Intervention: Injecting with a used needle
Number of subjects: 1770
Study 17329041 — intervention group
Group type: EXPERIMENTAL
Intervention: Intimate partner violence
Number of subjects: 1770
Study 15114122 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection microdome positioned in the parasternal area
Number of subjects: 260
Study 15114122 — intervention group
Group type: COMPARATOR
Intervention: Injection microdome positioned in the lower lateral thoracic area
Number of subjects: 260
Study 11695500 — intervention group
Group type: EXPERIMENTAL
Intervention: Contextual Memory Test (CMT)
Number of subjects: 60
Study 11695500 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued condition (contextual)
Number of subjects: 60
Study 11695500 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-awareness estimation
Number of subjects: 60
Study 11695500 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of contextual and association strategies
Number of subjects: 60
Study 9151028 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% hydroxyethyl starch
Number of subjects: 36
Study 9151028 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% gelatin
Number of subjects: 36
Study 9151028 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% human albumin
Number of subjects: 36
Study 9151028 — intervention group
Group type: COMPARATOR
Intervention: Control (all groups)
Number of subjects: 36
Study 7903975 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4 lymphocyte count monitoring
Number of subjects: 1020
Study 7903975 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportionate rates of decline in CD4 counts
Number of subjects: 1020
Study 7903975 — intervention group
Group type: EXPERIMENTAL
Intervention: Declines in CD4 counts in specific subgroups
Number of subjects: 1020
Study 3153025 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma infusions (plasma group, n = 39)
Number of subjects: 79
Study 3153025 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 40)
Number of subjects: 79
Study 30649925 — intervention group
Group type: EXPERIMENTAL
Intervention: Two continuous glucose monitors (CGMs)
Number of subjects: 43
Study 30649925 — intervention group
Group type: EXPERIMENTAL
Intervention: Two insulin pumps
Number of subjects: 43
Study 30649925 — intervention group
Group type: EXPERIMENTAL
Intervention: All system configurations (using CGMs and insulin pumps)
Number of subjects: 43
Study 28625655 — intervention group
Group type: EXPERIMENTAL
Intervention: Talc pleurodesis (TP)
Number of subjects: 61
Study 28625655 — intervention group
Group type: COMPARATOR
Intervention: Indwelling pleural catheter (IPC)
Number of subjects: 61
Study 26525477 — intervention group
Group type: EXPERIMENTAL
Intervention: Furasol sore throat gargle solution
Number of subjects: 40
Study 26525477 — intervention group
Group type: COMPARATOR
Intervention: Antibacterial therapy
Number of subjects: 40
Study 21905162 — intervention group
Group type: EXPERIMENTAL
Intervention: GBOT group intervention (n = 216)
Number of subjects: 442
Study 21905162 — intervention group
Group type: COMPARATOR
Intervention: Usual care (CRL group, n = 226)
Number of subjects: 442
Study 21262884 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human prolactin (r‐hPRL)
Number of subjects: 11
Study 18055921 — intervention group
Group type: EXPERIMENTAL
Intervention: Active capacitively coupled electric field stimulation applied for 15 hours per day until healed; supplemental calcium provided.
Number of subjects: 44
Study 18055921 — intervention group
Group type: COMPARATOR
Intervention: Placebo capacitively coupled electric field stimulation applied for 15 hours per day until healed; supplemental calcium provided.
Number of subjects: 44
Study 16481919 — intervention group
Group type: EXPERIMENTAL
Intervention: iomeprol 400 (400 mg iodine/mL)
Number of subjects: 40
Study 16481919 — intervention group
Group type: COMPARATOR
Intervention: iopromide 370 (370 mg iodine/mL)
Number of subjects: 40
Study 12590014 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (10 mg/day)
Number of subjects: 27
Study 12590014 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate (400 mg/day)
Number of subjects: 27
Study 10630797 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamed femoral nailing
Number of subjects: 170
Study 10630797 — intervention group
Group type: COMPARATOR
Intervention: Unreamed femoral nailing
Number of subjects: 170
Study 9106695 — intervention group
Group type: EXPERIMENTAL
Intervention: UC patients without PSC
Number of subjects: 87
Study 9106695 — intervention group
Group type: COMPARATOR
Intervention: UC patients with PSC
Number of subjects: 87
Study 8261677 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein intake (g/kg/day)
Number of subjects: 123
Study 8261677 — intervention group
Group type: EXPERIMENTAL
Intervention: Difference between protein-N intake and urea-N excretion
Number of subjects: 123
Study 8261677 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of protein intake and urea-N excretion
Number of subjects: 123
Study 8261677 — intervention group
Group type: EXPERIMENTAL
Intervention: Maroni's formula
Number of subjects: 123
Study 8261677 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary diaries
Number of subjects: 123
Study 3513667 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (60 mg/kg)
Number of subjects: 10
Study 3513667 — intervention group
Group type: COMPARATOR
Intervention: Saline pretreatment (control)
Number of subjects: 10
Study 30314294 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial health warning labels (HWLs) from Set A
Number of subjects: 1163
Study 30314294 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial health warning labels (HWLs) from Set B
Number of subjects: 1163
Study 30314294 — intervention group
Group type: COMPARATOR
Intervention: Text-only health warning labels
Number of subjects: 1163
Study 26857646 — intervention group
Group type: EXPERIMENTAL
Intervention: TDRD1 mRNA levels
Number of subjects: 99
Study 26857646 — intervention group
Group type: EXPERIMENTAL
Intervention: TMPRSS2-ERG mRNA presence
Number of subjects: 99
Study 26857646 — intervention group
Group type: EXPERIMENTAL
Intervention: TDRD1 mRNA level
Number of subjects: 99
Study 26857646 — intervention group
Group type: EXPERIMENTAL
Intervention: TMPRSS2-ERG expression
Number of subjects: 99
Study 26857646 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis of mRNA expression of 11 candidate genes combined with KLK3, serum PSA, percentage-free PSA, and prostate volume
Number of subjects: 99
Study 26857646 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum PSA, percentage-free PSA, and prostate volume
Number of subjects: 99
Study 24291239 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 weeks pegylated interferon and ribavirin
Number of subjects: 136
Study 24291239 — intervention group
Group type: COMPARATOR
Intervention: 48 weeks pegylated interferon and ribavirin
Number of subjects: 136
Study 24291239 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 weeks pegylated interferon and ribavirin (in patients with biopsy proven cirrhosis)
Number of subjects: 136
Study 24291239 — intervention group
Group type: COMPARATOR
Intervention: 48 weeks pegylated interferon and ribavirin (in patients with biopsy proven cirrhosis)
Number of subjects: 136
Study 24291239 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 weeks pegylated interferon and ribavirin (in patients with cirrhosis proven on imaging)
Number of subjects: 136
Study 24291239 — intervention group
Group type: COMPARATOR
Intervention: 48 weeks pegylated interferon and ribavirin (in patients with cirrhosis proven on imaging)
Number of subjects: 136
Study 23041995 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe vera gel
Number of subjects: 40
Study 23041995 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone acetonide
Number of subjects: 40
Study 20390593 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharide supplementation (3.6 g per day, taken as a teaspoon twice daily for 12 weeks)
Number of subjects: 109
Study 20390593 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 109
Study 17456665 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-guided total IV anesthesia with propofol
Number of subjects: 44
Study 17456665 — intervention group
Group type: COMPARATOR
Intervention: Clinically guided total IV anesthesia with propofol
Number of subjects: 44
Study 16134993 — intervention group
Group type: EXPERIMENTAL
Intervention: Fel d 1 peptides (approximately 300 mug in increasing, divided doses)
Number of subjects: 16
Study 16134993 — intervention group
Group type: EXPERIMENTAL
Intervention: Fel d 1 peptides (in open study)
Number of subjects: 16
Study 16134993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 12218725 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE, 0.625 mg daily) for 3 months, followed by CEE combined with low-dose medroxyprogesterone acetate (MPA, 2.5 mg daily) for an additional 3 months
Number of subjects: 38
Study 12218725 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 38
Study 10099941 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaio (200 g daily)
Number of subjects: 32
Study 10099941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 7557852 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon treatment
Number of subjects: 85
Study 2112338 — intervention group
Group type: COMPARATOR
Intervention: 10 mg nitroglycerin (NTG) patch
Number of subjects: 30
Study 213081 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-sitosterol
Number of subjects: 15
Study 30957868 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition of the spectral nature of heart failure and its implications for future trial designs.
Number of subjects: 0
Study 30957868 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathophysiological reasoning against the classification of HF based solely on LVEF.
Number of subjects: 0
Study 29021121 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU + CBT4CBT
Number of subjects: 71
Study 29021121 — intervention group
Group type: COMPARATOR
Intervention: TAU only
Number of subjects: 71
Study 26418918 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP‐ACFP (Mi Paste Plus)
Number of subjects: 786
Study 26418918 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP‐ACP (GC Tooth Mouse)
Number of subjects: 786
Study 26418918 — intervention group
Group type: COMPARATOR
Intervention: Fluoride varnish (Duraphat)
Number of subjects: 786
Study 23257248 — intervention group
Group type: EXPERIMENTAL
Intervention: Degarelix (240/80 mg monthly for 12 weeks)
Number of subjects: 244
Study 23257248 — intervention group
Group type: COMPARATOR
Intervention: Goserelin (3.6 mg monthly for 12 weeks) plus Bicalutamide (50 mg for 17 days initially)
Number of subjects: 244
Study 23257248 — intervention group
Group type: EXPERIMENTAL
Intervention: Degarelix
Number of subjects: 244
Study 23257248 — intervention group
Group type: COMPARATOR
Intervention: Goserelin plus Bicalutamide
Number of subjects: 244
Study 23257248 — intervention group
Group type: EXPERIMENTAL
Intervention: Degarelix (in patients with baseline International Prostate Symptom Score ≥13)
Number of subjects: 244
Study 23257248 — intervention group
Group type: COMPARATOR
Intervention: Goserelin plus Bicalutamide (in patients with baseline International Prostate Symptom Score ≥13)
Number of subjects: 244
Study 21288121 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX) dosed twice daily (BID)
Number of subjects: 55
Study 21288121 — intervention group
Group type: COMPARATOR
Intervention: Atomoxetine (ATX) dosed once daily (QD)
Number of subjects: 55
Study 19746679 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% hydroquinone/0.05% tretinoin skin care system + IPL
Number of subjects: 36
Study 19746679 — intervention group
Group type: COMPARATOR
Intervention: Placebo + IPL
Number of subjects: 36
Study 17941029 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy followed by prostatectomy
Number of subjects: 0
Study 15088884 — intervention group
Group type: COMPARATOR
Intervention: Low-dose flurbiprofen (LDF) alone, 50 mg q.d.
Number of subjects: 19
Study 15088884 — intervention group
Group type: COMPARATOR
Intervention: Subantimicrobial dose doxycycline (SDD) alone, 20 mg b.i.d.
Number of subjects: 19
Study 15088884 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of SDD plus LDF
Number of subjects: 19
Study 11235927 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (5.4 mg mean stable dose)
Number of subjects: 33
Study 11235927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 10193290 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 2.0 mg and glycopyrrolate 0.4 mg
Number of subjects: 100
Study 10193290 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 100
Study 8091148 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous oral pamidronate (APD), 1000 mg/day
Number of subjects: 27
Study 8091148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 2897764 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 200 mg daily
Number of subjects: 40
Study 2897764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 29544550 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC)
Number of subjects: 0
Study 29544550 — intervention group
Group type: COMPARATOR
Intervention: No IPC (control)
Number of subjects: 0
Study 26980346 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm temperature (31°C) during fasting and exercise sessions
Number of subjects: 22
Study 26980346 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm temperature (31°C) during oral glucose tolerance tests (OGTTs)
Number of subjects: 22
Study 26980346 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm temperature (31°C) during OGTTs
Number of subjects: 22
Study 26980346 — intervention group
Group type: COMPARATOR
Intervention: Control temperature (22°C) during fasting and exercise sessions
Number of subjects: 22
Study 26980346 — intervention group
Group type: COMPARATOR
Intervention: Control temperature (22°C) during OGTTs
Number of subjects: 22
Study 25765705 — intervention group
Group type: EXPERIMENTAL
Intervention: RM1 (≥3 days and/or nights of cough, wheeze, and/or medicine use) documented by parental diaries at 12 months corrected age
Number of subjects: 303
Study 25765705 — intervention group
Group type: EXPERIMENTAL
Intervention: RM2 (≥4 days and/or nights of cough, wheeze, and/or respiratory medicine use) documented by parental diaries at 12 months corrected age
Number of subjects: 303
Study 25765705 — intervention group
Group type: COMPARATOR
Intervention: BPD28d
Number of subjects: 303
Study 25765705 — intervention group
Group type: COMPARATOR
Intervention: BPD36w
Number of subjects: 303
Study 24385635 — intervention group
Group type: EXPERIMENTAL
Intervention: Everyday cognition
Number of subjects: 698
Study 24385635 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower cognitive performance
Number of subjects: 698
Study 24385635 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 698
Study 20873879 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone (15 mg)
Number of subjects: 24
Study 20873879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 18465717 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Dex) sedation
Number of subjects: 44